Triplet Therapy in Melanoma - Combined BRAF/MEK Inhibitors and Anti-PD-(L)1 Antibodies
- Author(s)
- Dixon-Douglas, JR; Patel, RP; Somasundram, PM; McArthur, GA;
- Details
- Publication Year 2022-08,Volume 24,Issue #8,Page 1071-1079
- Journal Title
- Current Oncology Reports
- Publication Type
- Review
- Abstract
- PURPOSE OF REVIEW: We provide an updated review of clinical trials evaluating the combination of BRAF/MEK inhibitors with anti-PD-(L)1 therapy (triplet therapy) for patients with advanced BRAF-mutant melanoma, accompanied by a summary of the biological evidence supporting this combination. RECENT FINDINGS: Resistance to BRAF/MEK inhibition and comparatively low response rates to immune checkpoint inhibitors remain clinical challenges in the treatment of melanoma. Preclinical data demonstrates that targeted therapy is immune-modulatory and synergises with immune checkpoint inhibition. Several randomised controlled trials have evaluated the combination of targeted therapy with immune checkpoint inhibition. Triplet therapy has shown improvements in progression-free survival and durability of response compared to BRAF/MEK inhibition alone; however, questions remain regarding the best clinical scenario for implementation of this regimen in the era of front-line immunotherapy.
- Keywords
- Humans; Immune Checkpoint Inhibitors/pharmacology/therapeutic use; *Melanoma/therapy; Mitogen-Activated Protein Kinase Kinases/therapeutic use; Protein Kinase Inhibitors/pharmacology; *Proto-Oncogene Proteins B-raf; Advanced melanoma; BRAF mutant; BRAF/MEK inhibitors; Immune checkpoint inhibitors; Immunotherapy
- Department(s)
- Medical Oncology; Laboratory Research
- PubMed ID
- 35366166
- Publisher's Version
- https://doi.org/10.1007/s11912-022-01243-x
- Open Access at Publisher's Site
https://doi.org/10.1007/s11912-022-01243-x- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-10-24 01:11:57
Last Modified: 2024-10-24 01:14:10